The medication is used in the management of human immunodeficiency virus type 1 (HIV-1) infection. The therapy is relevant for easing symptoms that are linked to organ-specific functional stress.

Managing Symptoms and Supporting Health

Intelence is applied to help manage manifestations that include symptoms related to systemic imbalance, such as fatigue and general malaise, and symptoms associated with immune weakness. This medication is commonly used across conditions where functional stability becomes affected, particularly in patients who have taken HIV medicines in the past. It is relevant when additional support for symptom management is appropriate in contexts involving recurrent or episodic manifestations, and is applicable within clinical settings that involve acute or disruptive symptom patterns.

It supports the body's natural defenses to ease the overall symptom load and helps patients cope more steadily with symptom fluctuations, contributing to general well-being during symptomatic phases.

“This supportive benefit is considered relevant for easing the overall symptom load and helps patients cope more steadily with symptom fluctuations.”

Quick Fact: Addressing Symptoms of Systemic Imbalance Intelence assists with managing symptoms that create noticeable physiological strain, which are often experienced in conditions characterized by periods of heightened symptoms.

Official Eligibility Profile for Intelence (Etravirine)

Official regulatory documents define the population groups permitted to use Intelence and those for whom use is restricted or prohibited. The medicine is primarily indicated for antiretroviral treatment-experienced patients with HIV-1 infection.

Category	Regulatory Classification
Populations for whom use is allowed	Adult patients. Pediatric patients 2 years of age and older who weigh at least 10 kg (22 lbs).
Populations for whom use is contraindicated	Patients with known hypersensitivity to Etravirine or its components.

---

• Condition-Specific Restrictions: Use is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) due to unstudied pharmacokinetics in this group. For those with moderate hepatic impairment (Child-Pugh Class B), caution is advised. No dose adjustment is required for patients with renal impairment.
• Age-Related Limits: The medicine is not recommended for children less than 2 years of age. Use in patients over 65 years of age is associated with limited information.
• Pregnancy and Lactation: Breastfeeding is not recommended for patients receiving Etravirine because of the risk of HIV-1 transmission to the infant and the presence of Etravirine in breast milk.

The official regulatory profile of Intelence (Etravirine) details specific pharmacokinetic interactions stemming from its metabolic properties. Etravirine is documented as a dual modulator of Cytochrome P450 (CYP) enzymes: an inducer of CYP3A4 and an inhibitor of CYP2C9 and CYP2C19. It is also an inhibitor of P-glycoprotein (P-gp), a drug transporter. These combined effects may increase or decrease the plasma concentration of co-administered medicines that are substrates for these enzymes or transporters.

Co-administration with several substances is generally not recommended by regulatory authorities. This includes other Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), as well as strong CYP3A4 inducers such as Rifampicin and the herbal product St. John's Wort. These agents can significantly reduce Etravirine plasma levels. Specific ritonavir-boosted protease inhibitors, like Tipranavir/Ritonavir, are also advised against co-administration. Conversely, the official label notes that co-administration with Lopinavir/Ritonavir may increase Etravirine's systemic exposure.

A mandatory food-based pharmacokinetic requirement exists: the medicine must be taken with a meal to ensure adequate absorption and systemic exposure. Furthermore, use is not recommended in patients with severe hepatic impairment (Child-Pugh Class C), as the pharmacokinetic and interaction profiles have not been established in this population.

Non-Nucleoside Inhibition of the Reverse Transcriptase Enzyme

Intelence (etravirine) is a diarylpyrimidine classified as a non-nucleoside reverse transcriptase inhibitor (NNRTI). Its mechanism is based on non-competitive binding to the non-nucleoside binding pocket (NNBP) within the HIV-1 reverse transcriptase (RT) enzyme. This binding induces a conformational change in the enzyme's structure, thereby blocking its polymerase active site and resulting in the inhibition of the viral RNA-to-DNA conversion process.

Structural Modulation of the Replication Cascade

The molecular structure of etravirine provides binding flexibility that allows for maintained RT inhibition even when the enzyme has undergone specific structural modifications (mutations) that confer resistance to first-generation NNRTIs. This structural interference is maintained despite target site polymorphism. By inhibiting the initial DNA synthesis step, etravirine modifies early molecular steps that suppress the signaling sequence necessary for the virus to integrate into the host cell's DNA and complete the viral replication cascade.

How to Use Intelence

Intelence (etravirine) is strictly used as an oral medication administered in a specific combination therapy with other antiretroviral agents for the long-term management of HIV-1 infection. The medicine is available as 25 mg, 100 mg, and 200 mg tablets.

---

Official Dosing and Administration

The administration pattern is precisely defined to ensure proper use.

Feature	Official Administration Guidelines
Standard Adult Dose	200 mg per dose.
Dosing Frequency	Administered twice daily (approximately every 12 hours).
Timing	Must be taken following a meal (i.e., with food).

---

Preparation and Adjustments

The tablets can be either swallowed whole with a liquid or, if required, administered as a liquid suspension.

To prepare the suspension, the tablet is dispersed in about 5 mL of water, stirred until milky, and consumed immediately. The glass must then be rinsed with an additional 15 mL of liquid, such as water, milk, or orange juice, to ensure the full dose is taken. Note that warm or carbonated beverages must be avoided during this preparation.

For chronic use, if a dose is missed by within 6 hours of the usual time, it should be taken with a meal; otherwise, the dose should be skipped, and the regular schedule resumed. No dose adjustment is required for patients with mild or moderate hepatic impairment or those with renal impairment. Pediatric patients (at least 2 years of age and at least 10 kg) are managed with weight-based dosing, not exceeding the adult 200 mg twice-daily maximum.

Research Evidence / Overview of Studies for Intelence

Clinical trials have studied Intelence (etravirine) as an agent for the study of HIV-1 infection, primarily focused on patient groups who had already received other HIV medicines.

---

Evidence for Use in Antiretroviral Treatment-Experienced Adults

The research base for etravirine in adults includes two large, multinational Phase III Randomized Controlled Trials (RCTs) (DUET-1 and DUET-2). These studies examined etravirine combined with other antiretroviral agents in heavily treatment-experienced adults with confirmed HIV-1 drug resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs). Researchers monitored virologic response (viral load reaching undetectable levels, typically <50 copies/mL) and changes in CD4+ T-cell counts.

Evidence for Use in Antiretroviral Treatment-Experienced Children

The research examining etravirine in children (aged 6 to less than 18 years) relies on Phase II open-label studies. A key focus of this research was characterizing drug exposure to ensure it reached levels similar to those studied in adults. Investigators monitored virologic and immunologic outcomes over the study period. Research results are not established for children younger than two years of age.

---

Limited Evidence and Research Gaps

The evidence includes patterns observed over 48 weeks and up to 96 weeks of follow-up from pooled data and extension studies. Long-term effects and outcomes over periods substantially longer than two years are not entirely characterized by the existing pivotal research.

Key research gaps include limited available data for the geriatric population (age 65 and older) and patients with severe hepatic impairment. Furthermore, research results are not established for use in treatment-naïve patients (those who have never taken antiretroviral therapy before).

Key Studies & References

1. Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study

Common questions about Intelence (FAQ)

Q: What is Intelence (etravirine) and how does it work?

Intelence (etravirine) is a prescription medicine used in combination with other antiretroviral agents to treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults and children at least 2 years of age. It belongs to a class of medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs).

It works by attaching to the HIV enzyme reverse transcriptase and blocking its ability to create DNA from RNA. This prevents the virus from replicating and infecting new cells, which helps reduce the amount of HIV in the body (viral load) and increases the number of CD4+ T cells (a type of white blood cell that fights infection).

---

Q: What are the key potential side effects of Intelence?

The most common side effects of Intelence can include rash, nausea, diarrhea, fatigue, and headache.

More serious, but less common, side effects have included severe skin reactions (including Stevens-Johnson syndrome), liver problems (hepatotoxicity), and hypersensitivity reactions.

Always discuss your medical history and all current medications with your healthcare provider before starting Intelence, as they can explain the complete risk profile based on your individual health status.

---

Q: Can Intelence be taken with food?

Yes. Intelence must be taken after a meal. It is important to take the medicine this way because eating a meal increases the amount of Intelence absorbed into your body, which helps the medicine work properly. The meal does not need to be high-fat.

---

Q: What should I do if I miss a dose of Intelence?

If you realize you have missed a dose, take it as soon as you remember, following a meal, unless it is almost time for your next dose. In that case, skip the missed dose and continue with your regular schedule. Do not double the dose to make up for a missed one.

If you frequently forget to take your medicine, talk to your healthcare provider about ways to help you remember.

---

Q: Are there any drugs that should not be taken with Intelence?

Yes, Intelence can interact with many other medicines. It is important to inform your healthcare provider about all prescription, nonprescription, and herbal products you are taking.

Some medicines that should not be taken with Intelence include:

• Certain anticonvulsants (e.g., carbamazepine, phenytoin, phenobarbital)
• Certain antimycobacterials (e.g., rifampin)
• Certain herbal supplements (e.g., St. John's wort)
• Other specific antiretrovirals (e.g., tipranavir/ritonavir)

These are not complete lists. Your healthcare provider will review your current medications to ensure there are no unsafe interactions.

Storage Conditions

Intelence tablets must be stored at a controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). To maintain the product's quality, the medicine must be protected from moisture.

Container and Handling Rules

Storage requires keeping the tablets in the original container and ensuring the bottle is tightly closed. The bottle contains desiccant packets (drying agents) which must remain inside to protect the medicine. Once a dispersible tablet is mixed with liquid for administration, the solution must be drunk immediately.

Disposal and Safety

Intelence must be kept out of the reach and sight of children. Unused or expired tablets should be disposed of by following official guidelines from the FDA or by consulting a pharmacist, and should not be thrown into household waste.